{"id":3292,"date":"2025-06-19T15:11:24","date_gmt":"2025-06-19T15:11:24","guid":{"rendered":"https:\/\/healthyretirementnews.com\/index.php\/2025\/06\/19\/fda-approves-twice-a-year-injection-for-hiv-prevention\/"},"modified":"2025-06-19T15:11:24","modified_gmt":"2025-06-19T15:11:24","slug":"fda-approves-twice-a-year-injection-for-hiv-prevention","status":"publish","type":"post","link":"https:\/\/healthyretirementnews.com\/index.php\/2025\/06\/19\/fda-approves-twice-a-year-injection-for-hiv-prevention\/","title":{"rendered":"FDA approves twice-a-year injection for HIV prevention"},"content":{"rendered":"<div data-uri=\"cms.cnn.com\/_components\/action-bar\/instances\/cmbgtspnr002j26ntfn9a6iwf@published\" data-label-id-prefix=\"action-bar-start-of-article\" class=\"action-bar\" data-dynamic-breakpoint-placement=\"{&quot;extraLarge&quot;:{&quot;placement&quot;:&quot;.layout-article-elevate__left&quot;}}\" data-expand-conditions=\"{&quot;follow&quot;:{&quot;extraLarge&quot;:{&quot;alwaysExpand&quot;:true}},&quot;shareOptions&quot;:{&quot;large&quot;:{&quot;maxNumOfActions&quot;:1},&quot;medium&quot;:{&quot;maxNumOfActions&quot;:1},&quot;extraLarge&quot;:{&quot;withAction&quot;:&quot;follow&quot;,&quot;maxNumOfActions&quot;:2}}}\">\n<div class=\"action-bar__overlay\"><\/div>\n<div class=\"action-bar__action-sheet\">\n<div class=\"action-bar__action-sheet--header\">\n<div class=\"action-bar__action-sheet--header-title\"><\/div>\n<div class=\"action-bar__action-sheet--header-close\">                            <\/div>\n<\/p>\n<\/div>\n<div class=\"action-bar__action-sheet--action\" data-title=\"follow\">\n<div data-uri=\"cms.cnn.com\/_components\/follow-topics-bar\/instances\/cmbgtspnr002n26nt9uif7gno@published\" data-unauth-redirect=\"\/account\/register\/follow\" data-embed-max-topics=\"\" class=\"follow-topics-bar follow-topics-bar_overlay follow-topics-bar--hide\">\n<div class=\"follow-topics-bar_overlay__inner\">\n<div class=\"follow-topics-bar_overlay__scroll-wrapper\">                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmbgtspnr002o26nt0gs3bf0p@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"New in medicine\" data-id=\"24c5535c-fbd9-44e1-874d-d8ff9577aaa4\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">New in medicine<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmbgtspnr002o26nt0gs3bf0p@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Wellness\" data-id=\"a3dee75f-6666-4b55-82a6-7f419e85b37e\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Wellness<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmbgtspnr002o26nt0gs3bf0p@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Prescription drugs\" data-id=\"f32c00b3-1166-47be-a590-74882550645e\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Prescription drugs<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmbgtspnr002o26nt0gs3bf0p@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Federal agencies\" data-id=\"874fe3a3-ab02-4ed7-8d3b-417b95049613\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Federal agencies<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>        <\/div>\n<div class=\"follow-topics-bar_overlay__fade follow-topics-bar_overlay__fade--hide\"><\/div>\n<p>                      See all topics              <\/p><\/div>\n<\/div>\n<\/div>\n<div class=\"action-bar__action-sheet--action\" data-title=\"share options\">\n<div data-uri=\"cms.cnn.com\/_components\/social-share\/instances\/cmbgtspnr002m26nt5orqb3jd@published\" class=\"social-share_labelled-list\">\n<div class=\"social-share_labelled-list__share-links vossi-social-share_labelled-list\" data-type=\"share-links\">        <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/www.facebook.com\/dialog\/share?app_id=80401312489&amp;href=https%3A%2F%2Fwww.cnn.com%2F2025%2F06%2F18%2Fhealth%2Fhiv-lenacapavir-fda-approval&amp;display=popup\" data-type=\"facebook\" aria-label=\"share with facebook\" title=\"Share with Facebook\">                                <span class=\"social-share_labelled-list__share-links--label\">Facebook<\/span>        <\/button>        <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/twitter.com\/intent\/tweet?text=Check%20out%20this%20article%3A&amp;url=https%3A%2F%2Fwww.cnn.com%2F2025%2F06%2F18%2Fhealth%2Fhiv-lenacapavir-fda-approval\" data-type=\"x\" aria-label=\"share with x\" title=\"Share with X\">                                <span class=\"social-share_labelled-list__share-links--label\">Tweet<\/span>        <\/button>                                        <span class=\"social-share_labelled-list__share-links--label\">Email<\/span>                <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/www.cnn.com\/2025\/06\/18\/health\/hiv-lenacapavir-fda-approval\" data-type=\"copy\" aria-label=\"copy link to clipboard\" title=\"Copy link to clipboard\">                                <span class=\"social-share_labelled-list__share-links--label\">Link<\/span>        <\/button>        <\/p>\n<div class=\"social-share_labelled-list__copied\" data-type=\"message\">                        Link Copied!        <\/div>\n<\/p>\n<\/div>\n<p>    <button class=\"social-share_labelled-list__open\" data-type=\"open\" aria-label=\"open social share\" title=\"Open social share\">            <\/button>    <button class=\"social-share_labelled-list__close\" data-type=\"close\" aria-label=\"close social share\" title=\"Close social share\">            <\/button><\/div>\n<\/p>\n<\/div>\n<\/div>\n<div class=\"action-bar__buttons\">            <button class=\"action-bar__button\" data-title=\"follow\">                                        Follow            <\/button>            <button class=\"action-bar__button\" data-title=\"share options\">                                <\/button>    <\/div>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgtspnr002l26nt1irq74nl@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            A drug currently used to treat certain HIV infections has also, on Wednesday,<strong> <\/strong>received approval from the US Food and Drug Administration to be used to prevent HIV.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb00043b6m8gqp37da@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical trials, the drug was found to dramatically reduce the risk of infection and provide near-total protection against HIV, significantly more than the primary options available for pre-exposure prophylaxis or PrEP.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb00053b6mvgriryga@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots, such as injections every two months of the medication Apretude. But a twice-yearly shot of lenacapavir has now become another option in the prevention toolbox \u2013 making it the first and only such shot for HIV prevention.    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmbgtthf3000o3b6mo6iyuqyl@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cm0z9hby9000h1oqk0186d5dx@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"GettyImages-1980522398.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.6656666666666666\" data-original-height=\"1997\" data-original-width=\"3000\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-1980522398.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">The Gilead headquarters in Foster City, California, US, on Monday, Jan. 29, 2024. Gilead Sciences Inc. is scheduled to release earnings figures on February 6.<\/span>  <\/div><figcaption class=\"image__credit\">David Paul Morris\/Bloomberg\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">Twice-a-year injection reduced risk of HIV infection by 96%, drug company says \u2014 more than daily PrEP pill<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb00063b6mgyx826j9@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            With any PrEP drug, \u201cby having that medicine in your bloodstream or in your body, if you encounter HIV, it blocks it from taking hold. It arrests infection from taking hold,\u201d said Dr. Jared Baeten, senior vice president of clinical development and the virology therapeutic area head at Gilead Sciences.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgv6pb900043b6mu49ykune@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The human immunodeficiency virus or HIV, spread primarily through unprotected sex or sharing needles, attacks the body\u2019s immune system, and without treatment, it can lead to acquired immunodeficiency syndrome or AIDS. Although rates of new HIV infections have fallen in the US, about 1.2 million people are estimated to have HIV, and about 13% of them may not know it.    <\/p>\n<h2 class=\"subheader inline-placeholder subheader-elevate vossi-subheader vossi-subheader--size-h2\" data-editable=\"text\" data-uri=\"cms.cnn.com\/_components\/subheader\/instances\/cmbzhu94v00053b6m73endon5@published\" data-component-name=\"subheader\" id=\"people-can-get-it-privately\" data-article-gutter=\"true\">        \u2018People can get it privately\u2019<\/h2>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb00083b6m15qmw8ra@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            A study called the PURPOSE 2 trial found that just two shots a year of lenacapavir can reduce the risk of HIV infection by 96%, proving it to offer near-total protection against HIV. Another study, the PURPOSE 1 trial, found that lenacapavir demonstrated 100% efficacy for HIV prevention in women.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb00093b6mjccjteqh@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cLenacapavir is a unique option for people for HIV prevention because it\u2019s an injection given just twice a year. So people can get it privately, discreetly, and then set it and forget it and not have to think about it until six months later,\u201d Baeten said. \u201cFor many people, that might be the empowered, private option that might make HIV prevention workable in their lives.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbzht2m400003b6m7sw0v1g5@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            There continues to be a lot of stigma, fear and misinformation around HIV, said Ian Haddock, who participated in the PURPOSE 2 trial for lenacapavir.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00023b6mgw0ow0ld@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            When Haddock was a teenager living in rural Texas, he recalled, he faced some of that stigma.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00033b6m9sxljetf@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cThe first thing that was said when my family found out that I was queer was, \u2018You\u2019re going to get AIDS,\u2019 \u201d said Haddock, who does not live with HIV. \u201cSo that\u2019s the first thing I heard.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00043b6mnq5ur7on@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Now, at 37, Haddock knows that HIV does not discriminate. He works to break such misguided stereotypes about the LGBTQ+ community as the founder of a nonprofit called the Normal Anomaly Initiative, and he said he is proud to have participated in the clinical trial.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00053b6mpvwcf8gv@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cIt feels like a full-circle moment,\u201d he said.    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cmc0pc9jn00013b6myk29bw4q@published\" class=\"image_medium-elevate portrait image_medium__hide-placeholder\" data-image-variation=\"image_medium\" data-name=\"GettyImages-2152542103.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image_medium--eq-extra-small&quot;: 115, &quot;image_medium--eq-small&quot;: 300, &quot;image_medium--eq-large&quot;: 660}\" data-original-ratio=\"1.0704\" data-original-height=\"2676\" data-original-width=\"2500\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-2152542103.jpg?c=original\" data-editable=\"settings\" data-article-gutter=\"true\">\n<div class=\"image_medium__container \" data-image-variation=\"image_medium\" data-breakpoints=\"{&quot;image_medium--eq-extra-small&quot;: 115, &quot;image_medium--eq-small&quot;: 300, &quot;image_medium--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image_medium__metadata-container media__metadata-container\">\n<div class=\"image_medium__metadata media__metadata\">\n<div class=\"image_medium__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">Ian Haddock, shown at the 35th Annual GLAAD Media Awards New York in 2024, participated in a trial of lenacapavir.<\/span>  <\/div><figcaption class=\"image_medium__credit\">Bryan Bedder\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00063b6mhyo7f0xe@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Haddock said he started to take daily PrEP pills in 2015 to help reduce his risk of HIV, but sometimes they would give him an upset stomach or he would forget to take them.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0sv9nf00033b6mglgiznkc@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            In January 2024, when he learned about the lenacapavir clinical trial, he quickly enrolled. He had no side effects during the trial other than irritation at the injection site, he said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00083b6mt6pzf4fc@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Even though the trial has concluded, Haddock said, he plans to continue receiving lenacapavir injections twice a year, and he hopes the FDA approval will help raise awareness of HIV prevention tools.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj00093b6mfni3t054@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States \u2013 but \u201ceven though PrEP has been around since 2012, people don\u2019t really know what it is, and they often kind of conflate it to having HIV or being extremely promiscuous,\u201d Haddock said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc0m5tqj000a3b6mxma37rsk@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cSo this just opens up a completely new opportunity,\u201d he said of lenacapavir.    <\/p>\n<h2 class=\"subheader inline-placeholder subheader-elevate vossi-subheader vossi-subheader--size-h2\" data-editable=\"text\" data-uri=\"cms.cnn.com\/_components\/subheader\/instances\/cmc0m6bq3000c3b6mmhdpff7g@published\" data-component-name=\"subheader\" id=\"a-milestone-moment\" data-article-gutter=\"true\">        \u2018A milestone moment\u2019<\/h2>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000a3b6mgys3p2ft@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Last year, Gilead Sciences released data from the PURPOSE 2 trial that showed 99.9% of the participants who received an injection of lenacapavir twice a year for HIV prevention did not become infected.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000b3b6mv77fm3na@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            There were only two cases among 2,180 people, effectively proving 89% more effective than the PrEP pill Truvada. The trial was unblinded early because it met its key endpoints, allowing lenacapavir to be offered to all participants, and the drug was found to be well-tolerated.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000c3b6muvaj5egf@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cThe most common side effects, as you might expect, are injection-site reactions,\u201d Baeten said, such as rash or discomfort.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000e3b6m47jp4cca@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The PURPOSE 2 trial included cisgender men, transgender men, transgender women and nonbinary people 16 or older who had sex with partners assigned male at birth. Some of the study participants became pregnant during the trial and continued to receive lenacapavir during pregnancy without complications, Baeten said.    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmbgtu8nd000w3b6me3qh5pru@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/clyz34du3000h65p88yei2682@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"GettyImages-1330885428.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.5625879043600562\" data-original-height=\"1600\" data-original-width=\"2844\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-1330885428.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">Phase 3 trial data shows that a twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections.<\/span>  <\/div><figcaption class=\"image__credit\">Catherine Falls Commercial\/Moment RF\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">Twice-yearly shot proves successful at preventing HIV infection among women, trial data shows<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbtz6cxj00003b6muy1h07tx@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cThis is a milestone moment in the decades-long fight against HIV. With twice-yearly administration and remarkable efficacy, lenacapavir will help us prevent HIV on a scale never seen before,\u201d Daniel O\u2019Day, chairman and chief executive officer at Gilead Sciences, said in an emailed statement.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbtz9sq200053b6mryrrjsny@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cAfter 17 years of research and pioneering clinical trials, Gilead scientists have delivered the next frontier in HIV innovation: a prevention medicine with remarkable efficacy that only needs to be delivered twice a year,\u201d O\u2019Day said. \u201cIt\u2019s a true scientific breakthrough that could help millions of people around the world.\u201d    <\/p>\n<h2 class=\"subheader inline-placeholder subheader-elevate vossi-subheader vossi-subheader--size-h2\" data-editable=\"text\" data-uri=\"cms.cnn.com\/_components\/subheader\/instances\/cmc0rdhgj00023b6mj402xm0s@published\" data-component-name=\"subheader\" id=\"price-announcement-still-to-come\" data-article-gutter=\"true\">        Price announcement still to come<\/h2>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000f3b6m0tfcecfi@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Now that lenacapavir has been approved for prevention, people should be able to visit their providers and ask about the drug within two days, Gilead Sciences said in an email. The company added that it could take up to two months for someone to receive their first injections, based on coverage decisions.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmc24rmbs00023b6m8cux6ur1@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The list price for lenacapavir, when used for HIV prevention, will be announced soon, Baeten said. The list price is expected to be different from when lenacapavir is used for the treatment of multidrug-resistant HIV, in which other HIV medications have not worked and the patient meets certain other requirements for lenacapavir treatment.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000g3b6m4rl2d235@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            One study published in November in the Journal of Antimicrobial Chemotherapy found that for treatment, lenacapavir costs up to nearly $45,000 per person per year without insurance, as an average wholesale list price \u2013 but it could be mass-produced for less than $100 per person per year.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000h3b6mqko0ozjb@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The team of researchers behind the study projected a possible minimum price based on the drug\u2019s current ingredients, production models and cost models. They demonstrated that lenacapavir could be mass-produced for up to $93 per person per year, potentially falling to about $40 per person per year \u201cif voluntary licences are in place and competition between generic suppliers substantially improves.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgxlbs000013b6mdzion3an@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cVoluntary licensing and multiple suppliers are required to achieve these low prices,\u201d the researchers wrote in the study abstract. \u201cThis mechanism is already in place for other antiretrovirals.\u201d    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmbgtum5o000y3b6mlddj21kt@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/thumbnail-4240265939e8fe05a10453bce2977d50@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"Truvada HIV AIDS pills anti-retroviral drugs\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.6826666666666666\" data-original-height=\"2048\" data-original-width=\"3000\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/111129085735-truvada-hiv-aids-pills-anti-retroviral-drugs.jpg?q=w_3000,h_2048,x_0,y_0,c_fill\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">A pharmacist pours Truvada pills back into the bottle at Jack&#8217;s Pharmacy on November 23, 2010, in San Anselmo, California. <\/span>  <\/div><figcaption class=\"image__credit\">Justin Sullivan\/Getty Images\/File<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">HIV\/AIDS Fast Facts<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000i3b6mehgmozy1@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Lenacapavir is the latest HIV prevention shot to receive FDA approval. Apretude, made by GSK\u2019s ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval in the US in 2021.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000j3b6mf04exjcv@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The hope is that PrEP tools could lead to a total halt to new HIV infections in future generations, Baeten said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000k3b6mgy4zizlx@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cEvery one of us would like nothing more than to end this epidemic, and that\u2019s what really solid prevention can do for us \u2013 that coupled with testing and treatment,\u201d he said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgttajb000l3b6m29drknkm@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cI want this next generation to think about HIV as something that they can end in their lifetime, end in their generation. And I want their next generation to be one where they\u2019ve never had to think about HIV at all,\u201d he said. \u201cWe\u2019ve got this amazing opportune moment right now as a world to think about where we can be in the future. We can be a world without HIV.\u201d    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmbi0uei100013b6m916j2zyw@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cmbbns2of007726nn4qla8tp9@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"GettyImages-2213974207.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.6666666666666666\" data-original-height=\"1600\" data-original-width=\"2400\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-2213974207.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">People attend a rally, led by Sen. Angela Alsobrooks, outside the National Institutes of Health in Bethesda, Maryland, on May 10, 2025.<\/span>  <\/div><figcaption class=\"image__credit\">Bill Clark\/CQ-Roll Call, Inc.\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">HHS budget proposal details significant cuts to National Institutes of Health, other agencies<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgxb3kj00003b6m8vp5cam4@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The new FDA approval comes as the Trump administration has cut back funding for HIV-related research grants, HIV prevention and surveillance programs \ufeffthrough the US Centers for Disease Control and Prevention, and sharply curtailed global HIV efforts.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgxul2q000c3b6mrir4q346@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The administration\u2019s 2026 budget proposal includes the elimination of funding for HIV programs, totaling more than $1.5 billion, according to the HIV+Hepatitis Policy Institute.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgxs3nj000a3b6mborsirh5@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            With the approval of lenacapavir for PrEP, \u201cnow is not the time to pull the rug out from under HIV prevention,\u201d Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in an email.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmbgxv0lq000h3b6mqlf2wkmy@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cThe obliteration of CDC HIV prevention and surveillance programs is an absurd proposal that will just increase HIV infections and health costs down the road,\u201d he said. \u201cWe urgently call on Congress to reject these cuts in order to ensure that states and community-based organizations have the resources to prevent HIV, which is still a serious infectious disease and results in about 32,000 new cases each year.\u201d    <\/p>\n<\/p>\n<div>This post appeared first on cnn.com<\/div>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New in medicine Wellness Prescription drugs Federal agencies See all topics Facebook Tweet Email Link&hellip;<\/p>\n","protected":false},"author":1,"featured_media":3293,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-news"],"_links":{"self":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts\/3292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/comments?post=3292"}],"version-history":[{"count":0,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts\/3292\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/media\/3293"}],"wp:attachment":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/media?parent=3292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/categories?post=3292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/tags?post=3292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}